For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales
24th October 2025 Uncategorised 0Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. On Friday, Sanofi reported that Dupixent achieved a new standard as quarterly sales exceeded 4 billion euros for the first time. The performance helped overcome an 8% drop in vaccine sales for the French company.
More: For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales
Source: fierce